This is an update of the current status of the Antibodypedia initiative.
Antibodypedia Newsletter
In June Antibodypedia released version 9 of the database. The new version includes a number of new pages and improvements. We have also released a new initiative - the Affinity Binder Knockdown Initiative!
Some of the updates are:
Easily find antibodies that have been validated or are eligible for validation within the knockdown initiative.
Antibodies participating within the knockdown initiative are marked with a star, and a knockdown validated antibody has a filled green star and is given a score (scroll down to the Antibodypedia algorithm to read about the scores).
Find out more in the release notes.
Beta release of the Affinity Binder Knockdown Initiative
During the past year there has been a discussion about antibodies and reproducibility in the research community and in journals. There is a general frustration that antibodies are not working as expected. One way to confirm the antibody binding to a specific target is to use knockdown or knockout of the target protein. The mission of the Affinity Binder Knockdown Initiative is to collect data on confirmed antibody binding and make it public and freely available to all antibody users.
A public-private partnership
Using crowdsourcing the initiative hopes to get scientists, whom do knockdown experiments in their daily activities, to share their results. If the results are positive, i.e. where the knockdown is successful, validation data will be presented on Antibodypedia. In return the researchers are compensated by the participating companies in a refund program.Read more about the initiative here: Affinity Binder Knockdown Initiative
The beta version of the initiative was released on June 24 at the EuPA 2015 Congress in Milan and is now open for submissions.
Please join us and submit your knockdown results!
Contact us if you would like to know more.
Antibodies and the human genome
In beginning of July 2015, Antibodypedia listed over 1.8 million antibodies, from 64 providers, targeting gene-products from 19 378 human ORFs (94% of the human genome). This is an addition of almost half a million antibodies, 14 new providers, and 237 additional gene products since July 2014.
Images and references
The antibodies in Antibodypedia are ranked based on the knowledge associated with them; a validation and citation score determines the rank and order in which the antibodies are listed.
The current antibody listing is supported with more than 743 000 antibody validations and almost 206 000 references. Compared to July 2014 this is an addition of almost 210 000 images and more than 84 000 citations.
Our traffic
Visits, page views, and countries of origin
In Q2 of 2015, Antibodypedia received 64 381 visits, from 158 countries, comprising 172 435 page views. Just above half of the traffic originated in the United States (28%), Japan (8%), Germany (6%), China (6%), or United Kingdom (5%).
Top gene visits
In Q2 of 2015, our five most-commonly-visited genes were GSK3B, MKI67, GAPDH, CD274, and TP53. Cumulatively, these visits stood for 2.1% of all visited genes.
Get in touch!
Antibodypedia will be at the 14th HUPO World Congress in Vancouver, Canada, Sept 27-30. Visit our poster or come to the Human Antibody Initiative session on Monday, September 28.
Please send us your feedback: What's frustrating? What changes would you like to see? And what are we getting right?
Contact us on contact@antibodypedia.com if you have any questions or thoughts on how we can improve our service to you.
And finally, I want to thank you for your interest in Antibodypedia.
Tove Alm
Manager Antibodypedia